Therapeutic drug monitoring of targeted anticancer therapy

New oral targeted anticancer therapies are revolutionizing cancer treatment by transforming previously deadly malignancies into chronically manageable conditions. Nevertheless, drug resistance, persistence of cancer stem cells, and adverse drug effects still limit their ability to stabilize or cure...

Full description

Saved in:
Bibliographic Details
Published in:Biomarkers in medicine 2015-09, Vol.9 (9), p.887-893
Main Authors: Decosterd, Laurent A, Widmer, Nicolas, Zaman, Khalil, Cardoso, Evelina, Buclin, Thierry, Csajka, Chantal
Format: Article
Language:English
Subjects:
Antineoplastic agents
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antineoplastic drugs
Antitumor agents
blood concentrations
Blood levels
Breast cancer
Cancer therapies
Cancer treatment
Dosage
Dosage and administration
drug dosage adaptation
Drug dosages
Drug monitoring
Drug Monitoring - methods
Drug resistance
Estrogens
Health aspects
Humans
Kinases
liquid chromatography-tandem mass spectrometry
Lung cancer
Melanoma
Methods
Molecular Targeted Therapy - methods
Mutation
Neoplasms - drug therapy
Neoplasms - metabolism
Patients
personalized medicine
Pharmacokinetics
Plasma
protein kinase inhibitors
Proteins
Signal transduction
Stem cells
targeted anticancer therapy
Therapeutic drug monitoring
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:New oral targeted anticancer therapies are revolutionizing cancer treatment by transforming previously deadly malignancies into chronically manageable conditions. Nevertheless, drug resistance, persistence of cancer stem cells, and adverse drug effects still limit their ability to stabilize or cure malignant diseases in the long term. Response to targeted anticancer therapy is influenced by tumor genetics and by variability in drug concentrations. However, despite a significant inter-patient pharmacokinetic variability, targeted anticancer drugs are essentially licensed at fixed doses. Their therapeutic use could however be optimized by individualization of their dosage, based on blood concentration measurements via the therapeutic drug monitoring (TDM). TDM can increase the probability of therapeutic responses to targeted anticancer therapies, and would help minimize the risk of major adverse reactions.
ISSN:1752-0363
1752-0371
DOI:10.2217/bmm.15.78